Skip to content
Clinical Trials – home
CzechiaBack to Czechia

Clinical trials in Konska

8 clinical trials in Konska, Czechia. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Konska at a glance
8
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

8 trials in Konska

Open in trial search

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Sponsor:Novo Nordisk A/S
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center

Hypertrophic cardiomyopathy

Not yet recruiting

Study on Mavacamten for Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Mavacamten
  • Sponsor:Myokardia Inc.

Cardiac failure

Not recruiting

Evaluation of Ziltivekimab in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.

A study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Cardiogenic shock

Not recruiting

Study on Istaroxime for Patients with Cardiogenic Shock Stage C

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Istaroxime
  • Sponsor:Windtree Therapeutics Inc.

Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Other cities in Czechia

The busiest research cities in the country

All 159 cities in Czechia

Clinical research in Konska

What the registry says about research in the country

01 Cardiovascular Emergency Studies

Innovative research focusing on cardiogenic shock, evaluating new therapeutic approaches for patients with severe cardiovascular complications. These trials aim to improve blood pressure management in critical conditions.

  • Emergency cardiovascular care
  • Blood pressure management
  • Critical care interventions

Current studies explore novel treatments for patients requiring urgent cardiovascular support.

02 Structural Heart Disease Research

Advanced investigations into hypertrophic cardiomyopathy, utilizing cardiac imaging to assess therapeutic effectiveness. These trials examine how new medications affect heart chamber structure and function.

  • Cardiac imaging studies
  • Heart muscle disorders
  • Therapeutic monitoring

Research focuses on innovative treatments to address cardiac structural abnormalities.

03 Post-Heart Attack Care

Comprehensive studies evaluating treatments for acute coronary syndrome, focusing on preventing subsequent cardiovascular events. These trials assess new medications for improved patient outcomes.

  • Cardiovascular prevention
  • Secondary prevention strategies
  • Long-term cardiac care

Research aims to reduce recurring cardiovascular complications in post-heart attack patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.